{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T16:20:59Z","timestamp":1759422059874,"version":"3.37.3"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,2,19]],"date-time":"2019-02-19T00:00:00Z","timestamp":1550534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,2,19]],"date-time":"2019-02-19T00:00:00Z","timestamp":1550534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The neuroprotective agent 3-hydroxymorphinan (3-HM) is a well-documented and highly safe therapeutic intervention for the inflammatory-related effects of Parkinson\u2019s disease (PD). However, the bioavailability of 3-HM is very low due to the rapid first-pass metabolism of the phenolic moiety. In the present study, we sought to improve the metabolic stability and overall pharmacokinetic profile of 3-HM. Based on an iterative design process that a suitably arranged heterocycle with an NH group would serve as the metabolically stable isostere of the phenolic group, we designed and synthesized two analogues of 3-HM. Benzimidazolone compound <jats:bold>8<\/jats:bold> (imidazolone-morphinan) was comparable in activity to 3-HM against lipopolysaccharide (LPS)-induced inflammatory responses in microglial BV2 cells and <jats:italic>in vivo<\/jats:italic> animal experiments (MPTP-induced PD mouse model). Moreover, the <jats:italic>in vitro<\/jats:italic> study showed that imidazolone-morphinan was non-toxic to microglia, indicating its high safety. Considering the favourable and unique preclinical profiles, compound <jats:bold>8<\/jats:bold> was nominated as a candidate for further clinical development.<\/jats:p>","DOI":"10.1038\/s41598-019-38911-1","type":"journal-article","created":{"date-parts":[[2019,2,19]],"date-time":"2019-02-19T11:04:24Z","timestamp":1550574264000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Design, Synthesis, and Biological Evaluation of Phenol Bioisosteric Analogues of 3-Hydroxymorphinan"],"prefix":"10.1038","volume":"9","author":[{"given":"Ziqiang","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuqi","family":"Bao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoguang","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1736-6749","authenticated-orcid":false,"given":"Guoning","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juxian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junmei","family":"Shang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chanjuan","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yucheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,2,19]]},"reference":[{"key":"38911_CR1","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1016\/S0140-6736(09)60492-X","volume":"373","author":"AJ Lees","year":"2009","unstructured":"Lees, A. J., Hardy, J. & Revesz, T. Parkinson\u2019s disease. Lancet 373, 2055\u20132066 (2009).","journal-title":"Lancet"},{"issue":"4","key":"38911_CR2","first-page":"196","volume":"140","author":"MC De Rijk","year":"1996","unstructured":"De Rijk, M. C. et al. Prevalence of Parkinsonism and of Parkinson\u2019s disease in elderly subjects; the \u2018Rotterdam study\u2019. Ned Tijdschr Geneeskd 140(4), 196\u2013200 (1996).","journal-title":"Ned Tijdschr Geneeskd"},{"issue":"1\u20133","key":"38911_CR3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00726-001-0111-9","volume":"23","author":"O Hornykiewicz","year":"2002","unstructured":"Hornykiewicz, O. L-DOPA: from a biologically inactive amino acid to a successful therapeutic agent. Amino Acids 23(1\u20133), 65\u201370 (2002).","journal-title":"Amino Acids"},{"issue":"1","key":"38911_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1212\/WNL.58.1.11","volume":"58","author":"JM Miyasaki","year":"2002","unstructured":"Miyasaki, J. M., Martin, W., Suchowersky, O., Weiner, W. J. & Lang, A. E. Practice parameter: initiation of treatment for Parkinson\u2019s disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 58(1), 11\u201317 (2002).","journal-title":"Neurology"},{"key":"38911_CR5","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1212\/01.WNL.0000101469.25169.A1","volume":"62","author":"T Pan","year":"2004","unstructured":"Pan, T., Le, W. & Jankovic, J. Slowing Parkinson\u2019s disease progression: recent dopamine agonist trials. Neurology 62, 343\u2013344 (2004).","journal-title":"Neurology"},{"key":"38911_CR6","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1007\/s00702-003-0081-z","volume":"110","author":"H Reichmann","year":"2003","unstructured":"Reichmann, H., Herting, B., Miller, A. & Sommer, U. Switching and combining dopamine agonists. J. Neural Transm. 110, 1393\u20131400 (2003).","journal-title":"J. Neural Transm."},{"key":"38911_CR7","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s00726-001-0110-x","volume":"23","author":"RM Kostrzewa","year":"2002","unstructured":"Kostrzewa, R. M., Kostrzewa, J. P. & Brus, R. Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson\u2019s disease. Amino Acids 23, 57\u201363 (2002).","journal-title":"Amino Acids"},{"key":"38911_CR8","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1517\/14656566.3.10.1393","volume":"3","author":"T Muller","year":"2002","unstructured":"Muller, T. Dopaminergic substitution in Parkinson\u2019s disease. Exper Opin. Pharmacother. 3, 1393\u20131403 (2002).","journal-title":"Exper Opin. Pharmacother."},{"key":"38911_CR9","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s00702-009-0334-6","volume":"117","author":"Q Li","year":"2010","unstructured":"Li, Q., Flood, P. M. & Hong, J. S. Neuroinflammation is a key player in Parkinson\u2019s disease and a prime target for therapy. J Neural Transm. 117, 971\u2013979 (2010).","journal-title":"J Neural Transm."},{"key":"38911_CR10","first-page":"83","volume":"86","author":"PL McGeer","year":"2001","unstructured":"McGeer, P. L., Yasojima, K. & McGeer, E. G. Inflammation in Parkinson\u2019s disease. Adv Neurol. 86, 83\u201389 (2001).","journal-title":"Adv Neurol."},{"key":"38911_CR11","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/S1474-4422(09)70062-6","volume":"8","author":"EC Hirsch","year":"2009","unstructured":"Hirsch, E. C. & Hunot, S. Neuroinflammation in Parkinson\u2019s disease: a target for neuroprotection? Lancet Neurol 8, 382\u2013397 (2009).","journal-title":"Lancet Neurol"},{"key":"38911_CR12","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1124\/jpet.102.043166","volume":"305","author":"Y Liu","year":"2003","unstructured":"Liu, Y. et al. Dextromethorphan protects dopaminergic neurons against inflammation-mediated degeneration through inhibition of microglial activation. J. Pharmacol. Exp. Ther. 305, 212\u2013218 (2003).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"38911_CR13","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1096\/fj.03-0983fje","volume":"18","author":"W Zhang","year":"2004","unstructured":"Zhang, W. et al. Neuroprotective effect of dextromethorphan in the MPTP Parkinson\u2019s disease model: role of NADPH oxidase. FASEB J. 18, 589\u2013591 (2004).","journal-title":"FASEB J."},{"key":"38911_CR14","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1096\/fj.04-1586fje","volume":"19","author":"W Zhang","year":"2005","unstructured":"Zhang, W. et al. 3-hydroxymorphinan is neurotrophic to dopaminergic neurons and is also neuroprotective against LPS-induced neurotoxicity. FASEB J. 19, 395\u2013397 (2005).","journal-title":"FASEB J."},{"issue":"14","key":"38911_CR15","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1096\/fj.06-6006com","volume":"20","author":"W Zhang","year":"2006","unstructured":"Zhang, W. et al. 3-Hydroxymorphinan, a metabolite of dextromethorphan, protects nigrostriatal pathway against MPTP-elicited damage both in vivo and in vitro. FASEB J. 20(14), 2496\u20132511 (2006).","journal-title":"FASEB J."},{"key":"38911_CR16","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1254\/jphs.11R02CR","volume":"116","author":"EJ Shin","year":"2011","unstructured":"Shin, E. J. et al. Neuropsychotoxic and Neuroprotective Potentials of Dextromethorphan and Its Analogs. J Pharmacol Sci. 116, 137\u2013148 (2011).","journal-title":"J Pharmacol Sci."},{"key":"38911_CR17","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1021\/jm00016a016","volume":"38","author":"SA Glass","year":"1995","unstructured":"Glass, S. A., Corbin, A. E., Pugsley, T. A., Heffner, T. G. & Wiss, L. D. Synthesis and dopaminergic activity of pyridine analogues of 5-hydroxy-2 (dinpropylamino)tetralin. J. Med. Chem. 38, 3132\u20133137 (1995).","journal-title":"J. Med. Chem."},{"key":"38911_CR18","doi-asserted-by":"publisher","first-page":"5057","DOI":"10.1016\/0040-4020(95)98702-J","volume":"51","author":"CV Denyer","year":"1995","unstructured":"Denyer, C. V., Bunyan, H., Loakes, D. M., Tucker, J. & Gillam, J. Synthesis of a hexahydro-2H-imidazole[4,5-g]isoquinolin-2-one derivative as an isostere of catecholamine-based selective dopamine D1 antagonists. Tetrahedron 51, 5057\u20135066 (1995).","journal-title":"Tetrahedron"},{"key":"38911_CR19","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1021\/jm00028a007","volume":"37","author":"B Singh","year":"1994","unstructured":"Singh, B. et al. Novel cAMP PDE III inhibitors: imidazo [4, 5-b] pyridine-2(3H)-ones and thiazolo [4, 5-b] pyridine-2 (3H)-ones and their analogues. J. Med. Chem. 37, 248\u2013254 (1994).","journal-title":"J. Med. Chem."},{"key":"38911_CR20","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S0960-894X(00)00049-4","volume":"10","author":"J Bosch","year":"2000","unstructured":"Bosch, J., Roca, T., Perez, C. G. & Montanari, S. Synthesis and dopaminergic activity of heterocyclic analogues of 5,6-dihydroxy-2-aminotetralins. Bioorg. Med. Chem. Lett. 10, 563\u2013566 (2000).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"38911_CR21","doi-asserted-by":"publisher","first-page":"3408","DOI":"10.1021\/jm000023o","volume":"43","author":"JL Wright","year":"2000","unstructured":"Wright, J. L. et al. Subtype-selective N-methyl-D-aspartate receptor antagonists: synthesis and biological evalution of 1-(heteroarylalkynyl)-4-benzylpiperidines. J. Med. Chem. 43, 3408\u20133419 (2000).","journal-title":"J. Med. Chem."},{"key":"38911_CR22","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S0960-894X(01)00778-8","volume":"12","author":"RE Mewshaw","year":"2002","unstructured":"Mewshaw, R. E. et al. New generation dopaminergic agents. Part 8: heterocyclic bioisosteres that exploit the 7-OH-2-(Aminomethyl)chroman D2 template. Bioorg. Med. Chem. Lett. 12, 271\u2013274 (2002).","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"3","key":"38911_CR23","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1021\/jm030614p","volume":"48","author":"WL Wu","year":"2005","unstructured":"Wu, W. L. et al. Dopamine D1\/D5 receptor antagonists with improved pharmacokinetics: design, synthesis, and biological evaluation of phenol bioisosteric analogues of benzazepine D1\/D5 antagonists. J Med Chem. 48(3), 680\u2013693 (2005).","journal-title":"J Med Chem."},{"key":"38911_CR24","doi-asserted-by":"publisher","first-page":"3164","DOI":"10.1016\/j.bmc.2013.03.059","volume":"21","author":"B Gopishetty","year":"2013","unstructured":"Gopishetty, B. et al. Modification of agonist binding moiety in hybrid derivative 5\/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-1-ol\/-2-amino versions: Impact on functional activity and selectivity for dopamine D2\/D3 receptors. Bioorg Med Chem. 21, 3164\u20133174 (2013).","journal-title":"Bioorg Med Chem."},{"issue":"1","key":"38911_CR25","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1021\/jm00211a036","volume":"20","author":"KC Rice","year":"1977","unstructured":"Rice, K. C. A rapid, high-yield conversion of codeine to morphine. J Med Chem. 20(1), 164\u2013165 (1977).","journal-title":"J Med Chem."},{"key":"38911_CR26","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.neuroscience.2011.11.036","volume":"202","author":"XQ Bao","year":"2012","unstructured":"Bao, X. Q., Kong, X. C., Qian, C. & Zhang, D. FLZ protects dopaminergic neuron through activating protein kinase B\/mammalian target of rapamycin pathway and inhibiting RTP801 expression in Parkinson\u2019s disease models. Neuroscience 202, 396\u2013404 (2012).","journal-title":"Neuroscience"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-38911-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-38911-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-38911-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T06:10:43Z","timestamp":1671257443000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-38911-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,19]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["38911"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-38911-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2019,2,19]]},"assertion":[{"value":"9 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"2247"}}